Literature DB >> 32965010

SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?

V Quagliariello1, A Bonelli, A Caronna, M C Lombari, G Conforti, M Libutti, R V Iaffaioli, M Berretta, G Botti, N Maurea.   

Abstract

NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32965010     DOI： 10.26355/eurrev_202009_22867

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN： 1128-3602            Impact factor:   3.507


  15 in total

Review 1.  Cardiovascular Tropism and Sequelae of SARS-CoV-2 Infection.

Authors:  Oleksandr Dmytrenko; Kory J Lavine
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

Review 2.  SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients.

Authors:  Vincenzo Quagliariello; Annamaria Bonelli; Antonietta Caronna; Gabriele Conforti; Martina Iovine; Andreina Carbone; Massimiliano Berretta; Gerardo Botti; Nicola Maurea
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

Review 3.  Cardiovascular Outcomes in the Acute Phase of COVID-19.

Authors:  Hiroki Nakano; Kazuki Shiina; Hirofumi Tomiyama
Journal:  Int J Mol Sci       Date:  2021-04-15       Impact factor: 5.923

4.  Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from COVID-19 patients.

Authors:  Iago C Schultz; Ana Paula S Bertoni; Márcia R Wink
Journal:  J Mol Med (Berl)       Date:  2022-01-29       Impact factor: 4.599

Review 5.  Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity.

Authors:  Annalisa Marcuzzi; Elisabetta Melloni; Giorgio Zauli; Arianna Romani; Paola Secchiero; Natalia Maximova; Erika Rimondi
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

6.  Design, synthesis and biological evaluation of 1,5-disubstituted α-amino tetrazole derivatives as non-covalent inflammasome-caspase-1 complex inhibitors with potential application against immune and inflammatory disorders.

Authors:  Fausta Ulgheri; Pietro Spanu; Francesco Deligia; Giovanni Loriga; Maria Pia Fuggetta; Iris de Haan; Ajay Chandgudge; Matthew Groves; Alexander Domling
Journal:  Eur J Med Chem       Date:  2021-11-18       Impact factor: 6.514

7.  Resveratrol improves cardiac function and left ventricular fibrosis after myocardial infarction in rats by inhibiting NLRP3 inflammasome activity and the TGF-β1/SMAD2 signaling pathway.

Authors:  Jinjin Jiang; Xiuping Gu; Huifeng Wang; Shibin Ding
Journal:  PeerJ       Date:  2021-05-28       Impact factor: 2.984

8.  Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression.

Authors:  Vincenzo Quagliariello; Massimiliano Berretta; Simona Buccolo; Martina Iovine; Andrea Paccone; Ernesta Cavalcanti; Rosaria Taibi; Monica Montopoli; Gerardo Botti; Nicola Maurea
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

Review 9.  The signal pathways and treatment of cytokine storm in COVID-19.

Authors:  Lan Yang; Xueru Xie; Zikun Tu; Jinrong Fu; Damo Xu; Yufeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-07

Review 10.  Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection.

Authors:  Muhammad Bilal Latif; Sudhanshu Shukla; Perla Mariana Del Rio Estrada; Susan Pereira Ribeiro; Rafick Pierre Sekaly; Ashish Arunkumar Sharma
Journal:  Transl Res       Date:  2021-12-03       Impact factor: 7.012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.